Development of a method for preparing octreotide derivative for diagnosis of neuroendocrine tumors

Currently the development of technologies for labeling somatostatin with technetium-99m for diagnosing radionuclide neuroendocrine tumors is under way. Somatostatin analogues are binded with technetium99m only by the preliminary addition of a chelating agent. Therefore, it is important to develop a method for preparation of an octreotide derivative by modifying octreotide with precursors: ligands with high chelating ability for its tight binding with technetium-99m. ω-Bis(pyridin-2-ylmethyl)amino)aliphatic acids can be used successfully as such precursors.

The purpose of the study was to develop a method for obtaining a new octreotide derivative for diagnosing neuroendocrine tumors.

Materials and methods. The somatostatin octreotide analogue was used as the object of the study; succinimid-1-yl 6-(bis(pyridin-2-ylmethyl)amino)hexanoate was used as a chelating agent. Methods of high performance liquid chromatography and mass spectrometry were used to separate and analyze the synthesized compounds.

Results. A method to produce an original octreotide derivative using a succinimid-1-yl 6-(bis(pyridin2-ylmethyl)amino)hexanoate as a chelating agent was proposed. The conditions of analytical and semipreparative HPLC for the analysis and purification of the active octreotide derivative (a monosubstituted derivative of the amino acid residue of D-phenylalanine) were suggested.

Conclusion. The synthesized derivative of octreotide has a chelating center for strong binding to technetium-99m in its structure, which can be useful for diagnosing neuroendocrine tumors. 

1. Sundin A., Rockall A. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead. Neuroendocrinology. 2012; 96 (4): 261–271. DOI: 10.1159/000342270.

2. Oberg K.E., Reubi J.C., Kwekkeboom D.J. et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010; 139 (3): 742–753. DOI: 10.1053/j.gastro.2010.07.002.

3. Eads J.R., Meropol N.J. A New Era for the Systemic Therapy of Neuroendocrine Tumors. The Oncologist. 2012; 17 (3): 326–338. DOI: 10.1634/theoncologist.2011-0356.

4. Strosberg J.R., Fine R.L., Choi J. et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011; 117: 268–275. DOI: 10.1002/cncr.25425.

5. Chernov V.I., Bragina O.D., Sinilkin I.G. et al. Radioimmunotherapy: current state of the problem. Vestnik Rentgenologii and Radiologii. 2016; 62 (1): 24–30 (in Russ.).

6. Chernov V.I., Bragina O.D., Sinilkin I.G. et al. Radioimmunotherapy in the treatment of malignancies. Questions of Оncology. 2016; 15 (2): 101–106 (in Russ.).

7. Chernov V.I., Bragina O.D., Sinilkin I.G. et al. Radioimmunotherapy in treatment of malignancies. Siber. J. Oncol. 2016; 97 (5): 306–313 (in Russ.).

8. Kwekkeboom D.J., Boen L.K., Martijn E. et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer. 2010; 17 (1): R53–73. DOI: 10.1677/ERC-09-0078.

9. Kulke M.H., Siu L.L., Tepper J.E. et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J. Clin. Oncol. 2011; 29 (7): 934–943. DOI: 10.1200/JCO.2010.33.2056.

10. Mikołajczak R., Maecke H.R. Radiopharmaceuticals for somatostatin receptor imaging. Nuclear Medicine Review. 2016; 19 (2): 126–132. DOI: 10.5603/NMR.2016.0024.

11. Krenning E.P., Kwekkeboom D.J., Bakker W.H. et al. Somatostatin receptor scintigraphy with [111-InDTPA-D-Phe] and [123-I-tyr]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993; 20 (8): 716–731.

12. Kunikowska J., Krґolicki L., Hubalewska-Dydejczyk A., Mikolajczak R. et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur. J. Nucl. Med. Mol. Imaging. 2011; 38 (10): 1788–1797. DOI: 10.1007/s00259-011-1833-x.

13. Kwekkeboom D.J., De Herder W.W., Kam B.L. et al. Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 2008; 26 (13): 2124–2130. DOI: 10.1200/JCO.2007.15.2553.

14. Makris G., Radford L., Gallazzi F. et аl. Synthesis and evaluation of fac-[ 99mTc/Re(CO)3] þ complexes with a new (N,S,N) bifunctional chelating agent: The first example of a fac- [Re(CO)3(N,S,N-sst2-ANT)] complex bearing a somatostatin receptor antagonist peptide. Journal of Organometallic Chemistry. 2016; 805: 100–107. DOI: 10.1016/j.jorganchem.2016.01.005.

15. Zhao R., Wang J. et аl. Efficacy of 99mTc-EDDA/HYNIC-TOC SPECT/CT scintigraphy in Graves’ ophthalmopathy. Am. J. Nucl. Med. Mol. Imaging. 2012; 2 (2): 242–247.

16. Wild D., Macke H.R., Waser B. et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur. J. Nucl. Med. Mol. Imaging. 2005; 32 (6): 724. DOI: 10.1007/s00259-004-1697-4.

17. Chernov V.I., Bragina O.D., Zelchan R.V. et al. Labeled somatostatin analogues in theranostics of neuroendocrine tumors. Medical Radiology and Radiation Safety. 2017; 3: 42–49 (in Russ.).

18. Behera A., De K., Chandra S. Synthesis, radiolabelling and biodistribution of HYNIC-Tyr3octreotide: a somatostatin receptor positive tumour imaging agent. J. Radioanal. Nucl. Chem. 2011; 290: 123–129. DOI: 10.1007/s10967-011-1156-1.

19. Skuridin V., Stasyuk E., Bragina O., Yusubov M., Chernov V., Larkina M., Zelchan R., Rogov A., Sinilkin I., Larionova L. Development of radiopharmaceutical based on mini-antibody for early cancer detection. Annual Congress of the European Association of Nuclear Medicine. Spain, Barcelona, October 15–19, 2016; 43: 465.

20. Sundararajan C., Besanger T.R., Labiris R. et al. Synthesis and сharacterization of rhenium and technetium-99m labeled insulin. J. Med. Chem. 2010; 53 (6): 2612–2621. DOI: 10.1021/jm100096c.